CHICAGO (Reuters) - Patients who got Eli Lilly and Co’s anti-clotting drug prasugrel after a coronary stent procedure had fewer stent-related clots than those on standard drug therapy, an analysis released on Saturday found. For stent patients, use of Lilly and Daiichi Sankyo Co Ltd’s prasugrel could offer better protection against heart attack, stroke and death from cardiovascular events than standard treatment with Plavix, researchers said in an article published in the journal Lancet’s online edition.
